AstraZeneca's Alexion buy takes first hit as Ultomiris fails in rare neurodegenerative disease

Bad news has struck first for AstraZeneca’s newly acquired Alexion rare disease franchise. AstraZeneca has decided to cap a trial testing Ultomiris in the rare neurodegenerative disease amyotrophic lateral sclerosis, citing lack of efficacy.

Related Keywords

Canada ,United Kingdom ,Massachusetts ,United States ,British ,Canadian ,Alexion Ultomiris ,Christopher Raymond ,Andrew Berens ,Piper Sandler ,Astrazeneca ,European Medicines Agency ,Massachusetts General ,Biohaven Pharmaceutical ,European Medicines ,Big Biotech ,Alexion ,Ultomiris Ravulizumab Cwvz ,Rare Diseases ,Marketing ,